What is Medacist?
Headquartered in Cheshire, CT, Medacist is at the forefront of drug diversion analytics, holding the sole U.S. patent in this specialized field. The company leverages advanced artificial intelligence (AI), machine learning, and data analytics to scrutinize clients' data. Its sophisticated platform identifies anomalous patterns throughout the entire drug lifecycle, from procurement and storage within clinical pharmacies to prescription and dispensation by healthcare professionals, and ultimately to patient administration. Medacist's suite of analytic services, powered by the Genesis healthcare data platform, empowers healthcare providers to detect potential abuse patterns for further investigation and intervention.
How much funding has Medacist raised?
Medacist has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Medacist
PPP
Public-Private Partnership
What's next for Medacist?
The substantial large-scale, late-stage funding context suggests Medacist is poised for significant scaling and market expansion. This capital infusion is likely to fuel further development of its AI-driven analytics, enhance its market penetration, and potentially explore new applications for its drug diversion detection technology. The company's focus on leveraging data to combat drug diversion positions it as a critical player in healthcare security and operational integrity.
See full Medacist company page
